Form 8-K - Current report:
SEC Accession No. 0001140361-22-014768
Filing Date
2022-04-15
Accepted
2022-04-15 17:18:07
Documents
14
Period of Report
2022-04-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10036443_8k.htm   iXBRL 8-K 29576
2 EXHIBIT 99.1 brhc10036443_ex99-1.htm EX-99.1 280919
6 image00001.jpg GRAPHIC 6251
  Complete submission text file 0001140361-22-014768.txt   473491

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btx-20220415.xsd EX-101.SCH 3929
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20220415_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20220415_pre.xml EX-101.PRE 16047
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10036443_8k_htm.xml XML 4245
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 22830625
SIC: 2834 Pharmaceutical Preparations